spacer
home > ebr > summer 2018 > gene therapy
PUBLICATIONS
European Biopharmaceutical Review

Gene Therapy

In 2014, following a quarter of a century roller coaster trajectory, Ledley et al published very optimistic conclusions after their examination of life cycles of gene therapy, stating “Gene therapy technologies are now achieving the level of maturity that innovation research and biotechnology experience suggest may be requisite for efficient product development” (1). Looking at the following, it seems that reality meets those odds:

• The first marketing authorisations granted in the Western countries (Strimvelis® for the rare immunodeficiency syndrome adenosine-deaminase-severe combined immunodeficiency (ADA-SCID), Imlygic® [HSV1-GMCSF] for melanoma, Kymriah® for acute leukocytic leukemia, Yescarta® for non-Hodgkin lymphoma, Luxturna® for Leber congenital amaurosis)
• The steady maturation of the field since the 1980s (>40,000 papers, nearly 20,000 patents, >2,500 clinical trials including >100 late stage Phase 2/3 or Phase 3 trials)
• Billions in capital investments and initial public offerings (IPOs) in gene therapy companies, the activity being now driven by large pharmaceutical companies (with a peak reached recently with the $8.7 billion acquisition of Avexis by Novartis)

Gene therapy is defined as the introduction of genetic material into patients with an intended curative, life-extending, or life-enhancing therapeutic benefit. The applications rely on a myriad of possibilities, including the transient or permanent genetic modification of the administered product or ex vivo-engineered tissue to produce proteins for internal, local, or systemic use, helping to replace or correct faulty genes (in the case of rare diseases), providing stimuli to regenerate tissues (in the case of brain or cardiac disorders), killing tissues, or enhancing defence mechanisms (in the case of cancer or infectious diseases).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Serge Braun PharmD, PhD, is Scientific Director of AFM-Téléthon, President of Genosafe (a CRO company dedicated to quality control of biotherapeutic products) and Director Neuromuscular diseases at Généthon. He has 10 years of experience in the neuromuscular diseases field in the academic sector and 10 years in the biotech sector as Vice President of Research of Transgene SA. Serge was also co-founder of Neurofit, a CRO specialised in preclinical testings, and Vice President of Alsace BioValley, the non-profit making organisation for the development of a major biotech cluster in Europe. He also serves as advisor for Venture Capital companies and bioclusters.
spacer
Dr Serge Braun
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Genome & Company Chooses Luina Bio to Supply Innovative Drug Productfor Clinical Trials Programme

Luina Bio, a leading biopharmaceutical manufacturing company in Australia, today announced it will develop and produce an innovative bacterial drug product for Genome & Company to support its clinical trials programme. The relationship signals Luina Bio’s first foray into Asia and further establishes its global leadership in the current Good Manufacturing Practise for microbiome projects.
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 
Industry Events

14th Annual Biomarkers Congress

21-22 February 2019, Manchester Central Convention Complex, UK

Oxford Global is proud to present for the 14th year our flagship Biomarkers Congress, taking place 21 – 22 February 2019 in Manchester, UK. An updated programme ensures you will benefit from talks on the latest strategies and technologies impacting growth in the biomarker industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement